Read by QxMD icon Read

Psychiatric Pharmacy

shared collection
229 papers 1000+ followers
By Dominique DeBold MCPHS University PharmD - Class of 2016, University of California B.S. Neuroscience - Class of 2005
Simon N Young
Recent clinical trials suggest that 3 single biological treatments have effects that persist. Based on research showing that the muscles involved in facial expressions can feed back to influence mood, a single trial diminishing glabella frown lines with botulinum toxin demonstrated a significant antidepressant effect for 16 weeks. Based primarily on research with animal models of depression suggesting that glutamate may be involved in depression, the N-methyl-D-aspartate antagonist ketamine has been tested in several trials...
March 2013: Journal of Psychiatry & Neuroscience: JPN
Marie Naughton, Gerard Clarke, Olivia F O'Leary, John F Cryan, Timothy G Dinan
INTRODUCTION: Recent research has seen low-dose ketamine emerge as a novel, rapid-acting antidepressant. Ketamine, an N-methy-d-aspartate (NMDA) receptor antagonist, leads to effects on the glutamatergic system and abnormalities in this neurotransmittor system are present in depression. This article aims to (1) review the clinical literature on low-dose ketamine as a rapid-acting antidepressant in affective disorders, (2) provide a critical overview of the limitations of ketamine and research attempts to overcome these (3) discuss the proposed mechanisms of action of ketamine and (4) point towards future research directions...
March 2014: Journal of Affective Disorders
James W Murrough, Dan V Iosifescu, Lee C Chang, Rayan K Al Jurdi, Charles E Green, Andrew M Perez, Syed Iqbal, Sarah Pillemer, Alexandra Foulkes, Asim Shah, Dennis S Charney, Sanjay J Mathew
OBJECTIVE: Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression. METHOD: This was a two-site, parallel-arm, randomized controlled trial of a single infusion of ketamine compared to an active placebo control condition, the anesthetic midazolam...
October 2013: American Journal of Psychiatry
Andreas Carlborg, Marcus Thuresson, Lena Ferntoft, Johan Bodegard
OBJECTIVES: The objective of this work was to study characteristics and clinical treatment patterns of bipolar disorder (BD) patients admitted to hospital and treated with quetiapine (immediate-release [IR] or extended-release [XR] formulations). METHODS: BD patients admitted to hospital and prescribed quetiapine IR were followed by linking two Swedish nationwide registries; the hospitalization and drug dispense registries [ identifier: NCT01455961]...
February 2015: Therapeutic Advances in Psychopharmacology
Saeed Shoja Shafti, Hamid Kaviani
INTRODUCTION: Around 40-60% of the patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Goal of this study was to compare the efficiency and safety of aripiprazole versus quetiapine, in patients with OCD, who did not respond effectively to fluvoxamine. METHOD: A total of 44 female inpatients with OCD, who did not respond successfully to fluvoxamine at maximum dose (300 mg/day) and duration (12 weeks), were assigned randomly, in a double-blind trial, to receive aripiprazole (n = 22) or quetiapine (n = 22), in addition to their SRI, for 12 weeks...
February 2015: Therapeutic Advances in Psychopharmacology
Karen Hodgson, Katherine E Tansey, Rudolf Uher, Mojca Zvezdana Dernovšek, Ole Mors, Joanna Hauser, Daniel Souery, Wolfgang Maier, Neven Henigsberg, Marcella Rietschel, Anna Placentino, Ian W Craig, Katherine J Aitchison, Anne E Farmer, Richard J B Dobson, Peter McGuffin
RATIONALE: Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P450 genotypic differences underlie the variation in treatment outcomes is inconclusive. OBJECTIVES: We explored the links between both P450 genotype and serum concentrations of antidepressant with antidepressant side effects, using data from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP), which is a large (n = 868), pharmacogenetic study of depressed individuals treated with escitalopram or nortriptyline...
July 2015: Psychopharmacology
Renata Fialho, Alison Burridge, Marco Pereira, Majella Keller, Alexandra File, Jeremy Tibble, Richard Whale
RATIONALE: Major depressive disorder is a common consequence of exposure to the pro-inflammatory cytokine interferon alpha, which is treated effectively with antidepressant medication. Antidepressant mode of action may conflict with interferon alpha's mechanism in treating hepatitis C however. OBJECTIVES: The purpose of this study is to prospectively explore, in a large naturalistic cohort, whether antidepressant exposure influenced end of treatment response of hepatitis C to interferon alpha...
May 2016: Psychopharmacology
A Wichniak, M Jarkiewicz, Ł Okruszek, A Wierzbicka, J Holka-Pokorska, J K Rybakowski
INTRODUCTION: Sleep-promoting antidepressants are of interest because they are used not only as antidepressants, but also to promote sleep. METHODS: We reviewed case reports describing the switch to mania during treatment with trazodone, mirtazapine, or agomelatine. RESULTS: Trazodone, mirtazapine, and agomelatine may induce manic symptoms. However, the risk of switching is related, first of all, to doses recommended for antidepressant treatment, administered without mood-stabilizer co-therapy...
May 2015: Pharmacopsychiatry
M Buoli, A C Altamura
RATIONALE: Cognitive impairment in schizophrenia patients is associated with poor outcome and it represents one of main challenges of pharmacological treatment. Unfortunately, second-generation antipsychotics have not yielded the expected results in the improvement of these symptoms. OBJECTIVE: The purpose of the present review paper is to summarize and discuss the available data about the efficacy of non-antipsychotic drugs in the treatment of cognitive symptoms of schizophrenia...
March 2015: Pharmacopsychiatry
D B Lee, Y S Woo, W M Bahk
OBJECTIVE: The aim of the present study is to demonstrate the effect of arotinolol on drug-induced tremor in psychiatric patients. METHODS: This is a case study of three psychiatric patients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of major depressive disorder who were treated in inpatient or outpatient psychiatric settings with antidepressant or antipsychotics. Patients developed tremor. Arotinolol was started to treat the tremor...
July 2015: Pharmacopsychiatry
Michelle A Worthington, Rif S El-Mallakh
No abstract text is available yet for this article.
April 2015: Journal of Clinical Psychopharmacology
Simon J Adamson, J Douglas Sellman, James A Foulds, Christopher M A Frampton, Daryle Deering, Alistair Dunn, John Berks, Lee Nixon, Gavin Cape
Despite the high rate of co-occurrence of major depression and alcohol dependence, the role of pharmacotherapy in their treatment remains unclear. In the new era of naltrexone for alcohol dependence, it is notable that only 1 study to date has examined the efficacy of antidepressant medication prescribed concurrently with naltrexone. We aimed to determine whether combining naltrexone with citalopram produced better treatment outcomes than naltrexone alone in patients with co-occurring alcohol dependence and depression, and to investigate whether either sex or depression type (independent or substance-induced depression) moderated treatment response...
April 2015: Journal of Clinical Psychopharmacology
Burc Aydin, Tugba Nayir, Selma Sahin, Aysegul Yildiz
No abstract text is available yet for this article.
April 2015: Journal of Clinical Psychopharmacology
Benedetto Vitiello
Practical clinical trials (PCTs) are randomized experiments under typical practice conditions with the aim of testing the "real-life" benefits and risks of therapeutic interventions. Influential PCTs have been conducted in cardiology, oncology, and internal medicine. Psychotropic medications are widely and increasingly used in medical practice. This review examines recent progress in conducting PCTs in psychopharmacology. The January 2000 to October 2014 MEDLINE, Scopus, and databases were searched for peer-reviewed publications of PCTs with at least 100 subjects per treatment arm...
April 2015: Journal of Clinical Psychopharmacology
Susan G Ball, Sarah Atkinson, JonDavid Sparks, Mark Bangs, Celine Goldberger, Sanjay Dubé
Long-term safety, tolerability, and efficacy of adjunctive edivoxetine hydrochloride (hereafter edivoxetine), a highly selective and potent norepinephrine reuptake inhibitor, was assessed in patients with major depressive disorder (MDD) experiencing partial response to selective serotonin reuptake inhibitor treatment. Data are from a multicenter, 54-week, open-label trial of adjunctive edivoxetine 12 to 18 mg once daily in patients with MDD who had experienced partial response by history to 6 or more weeks of current selective serotonin reuptake inhibitor therapy and who had a 17-item GRID Hamilton Rating Scale for Depression total score 16 or higher at study entry...
June 2015: Journal of Clinical Psychopharmacology
Kalliopi N Nikolaou, Ioannis Michopoulos, Athanasios Douzenis, Constantinos Papazahos, Charalabos Papageorgiou, Rossetos Gournellis
No abstract text is available yet for this article.
June 2015: Journal of Clinical Psychopharmacology
Joseph Ben-Sheetrit, Dov Aizenberg, Antonei B Csoka, Abraham Weizman, Haggai Hermesh
Emerging evidence suggests that sexual dysfunction emerging during treatment with selective serotonin reuptake inhibitors (SSRIs) and/or serotonin-norepinephrine reuptake inhibitors (SNRIs) persists in some patients beyond drug discontinuation (post-SSRI sexual dysfunction [PSSD]). We sought to identify and characterize a series of such cases and explore possible explanatory factors and exposure-response relationship. Subjects who responded to an invitation in a forum dedicated to PSSD filled out a survey via online software...
June 2015: Journal of Clinical Psychopharmacology
Rocco A Zoccali, Antonio Bruno, Maria Rosaria Anna Muscatello
Sertindole is an atypical antipsychotic reintroduced into the European market in 2005 after a reevaluation of its risks and benefits, under the agreement that close electrocardiographic screening would be conducted. It has a high affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and α1 adrenergic receptors. Moreover, sertindole shows modest affinity for H1-histaminergic and muscarinic receptors. The pharmacological properties, clinical efficacy, safety, and tolerability of sertindole are covered in this article based on a literature review from 1990 to 2014...
June 2015: Journal of Clinical Psychopharmacology
Anya K Bershad, Matthew G Kirkpatrick, Jacob A Seiden, Harriet de Wit
Many drugs, including alcohol and stimulants, demonstrably increase sociability and verbal interaction and are recreationally consumed in social settings. One drug, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), seems to produce its prosocial effects by increasing plasma oxytocin levels, and the oxytocin system has been implicated in responses to several other drugs of abuse. Here, we sought to investigate the effects of 2 other "social" drugs on plasma oxytocin levels--methamphetamine and alcohol...
June 2015: Journal of Clinical Psychopharmacology
Karen van der Weide, Jan van der Weide
INTRODUCTION: Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of greater than 50% of the prescribed drugs. Recently, the CYP3A4*22 allele was reported to be associated with lower CYP3A4 expression and activity. Quetiapine, an antipsychotic metabolized by only CYP3A4, displayed higher serum levels in CYP3A4*22 carriers. Aripiprazole, haloperidol, pimozide, and risperidone are antipsychotics that are metabolized by CYP3A4 and CYP2D6. We investigated to which degree the CYP3A4*22 single-nucleotide polymorphism affects serum concentrations of patients receiving these drugs and compared this with the influence of CYP2D6 polymorphisms...
June 2015: Journal of Clinical Psychopharmacology
2015-05-20 03:10:04
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"